Pink Sheet

Betting Generic: Part D, Patents and Proteins Drive Investment Surge

01 Oct 2007

• By Ramsey Baghdadi

Generic drug companies have been spurned by Wall Street in the past in favor of their brand manufacturing counterparts. With high generic use rates in Medicare Part D and a perceived inevitability of follow-on biologics, investment in pharmaceutical copycats is on the upswing.

Ramsey Baghdadi

When it comes to investing in health care, generic drugs don’t exactly get Wall Street’s heart racing. But based on...